Leskinen provided first quarter 2026 EPS guidance of $1 to $1.50 and full-year 2026 EPS guidance of $12 to $14, stating "At the midpoint, this represents over 20% growth and implies continued margin ...
Amgen (AMGN) stock is downgraded at Bernstein as the brokerage says 2026 may be a “waiting year” for the company. Read more here.